ACON - Aclarion, Inc. Latest News | Finranks

ACON - Aclarion, Inc. Latest News | Finranks

Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.

Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.

Stock has declined 99% since its IPO Believes Neal has repeatedly failed to fulfill his fiduciary responsibility Since 2021 Neal has received $240,000 Board compensation Accepted 20% pay increase in 2025 despite the company and shareholders suffering losses Believes Neal lacks appropriate skill set to serve on the Board Despite being on the Board for 9 years, Neal owns only two shares with a total market value of $6.24. Recently further entrenched himself with anti-takeover measures Questions employment of Jeff Thramann Believes Board could easily create meaningful shareholder value Notes stock trades below its net cash NEW YORK, NY / ACCESS Newswire / March 24, 2026 / Earlier today Ephraim Fields of Echo Lake Capital sent a letter to David K.

Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

BROOMFIELD, Colo., March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”).

Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”).

Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 Broomfield, CO, March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company's recent momentum and value-creating priorities for 2026.

Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

Broomfield, CO, March 17, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution)– Aclarion, Inc.

Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will participate in the 38th Annual ROTH Conference, March 22-24, 2026, in Dana Point, CA.

Videos

No Data

There is no data to display